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Abstract
Hormone replacement therapy associated risks, and the concomitant reluctance of usage, has instigated the search
for new generations of estrogen analogues that would maintain estrogen benefits without associated risks.
Furthermore, if these analogues display chemo-preventative properties in breast and endometrial tissues it would be
of great value. Both the selective estrogen receptor modulators as well as the selective estrogen receptor subtype
modulators have been proposed as estrogen analogues with improved risk profiles. Phytoestrogen containing
extracts of Cyclopia, an indigenous South African fynbos plant used to prepare Honeybush tea may serve as a
source of new estrogen analogues. In this study three extracts, P104, SM6Met, and cup-of-tea, from two species of
Cyclopia, C. genistoides and C. subternata, were evaluated for ER subtype specific agonism and antagonism both in
transactivation and transrepression. For transactivation, the Cyclopia extracts displayed ERα antagonism and ERβ
agonism when ER subtypes were expressed separately, however, when co-expressed only agonism was uniformly
observed. In contrast, for transrepression, this uniform behavior was lost, with some extracts (P104) displaying
uniform agonism, while others (SM6Met) displayed antagonism when subtypes were expressed separately and
agonism when co-expressed. In addition, breast cancer cell proliferation assays indicate that extracts antagonize cell
proliferation in the presence of estrogen at lower concentrations than that required for proliferation. Furthermore, lack
of uterine growth and delayed vaginal opening in an immature rat uterotrophic model validates the ERα antagonism
of extracts observed in vitro and supports the potential of the Cyclopia extracts as a source of estrogen analogues
with a reduced risk profile.
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Introduction
Hormone replacement therapy (HRT), estrogens alone or in
combination with progestins, is traditionally prescribed to
women undergoing menopausal transition to alleviate
symptoms associated with menopause [1], such as hot flashes,
night sweats, sleeping problems, vaginal dryness, and
osteoporosis [2-4]. However, a number of side effects have
been associated with the use of HRT, for example, an
increased occurrence of breast cancer [5,6], vaginal bleeding
[7], and heart disease or strokes [6,8]. These side effects have
led to reluctance among concerned consumers to use HRT and
instigated a search for new estrogen analogues with an
improved risk profile. Furthermore, it would be of great value if
these analogues should also display chemo-preventative
properties in breast tissue [9,10].
Estrogens elicit their biological effects by binding to
transcription factors called estrogen receptors (ERs) in the
target organ/tissue (uterus, ovary, vagina, liver, bone, and
breast) [11-13]. The ER exists as two subtypes, namely ERα
and ERβ [14]. Current estrogens in HRT activate both subtypes
of ER in all tissues [14-19]. This attribute is beneficial in bone
[18,20,21] and for hot flashes [18,21], but detrimental in the
breast [6,21,22] and uterus [21,23] as it increases the risk of
tumorigenesis. In contrast, the selective estrogen receptor
modulators (SERMs), although not ER subtype specific [24,25],
act as agonists in certain tissues, such as bone [26-28], and as
antagonists in others, such as breast [9,10,29]. Although, the
well-known SERMs, raloxifene and tamoxifen [30], have been
shown to decrease the risk of breast cancer [18,31,32] and
increase bone mineral density [26-28,33], they have also been
linked to an increased risk of venous thromboembolism and
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occurrence of hot flashes, and can stimulate endometrial
growth [28,34-36]. SERMs are thus not considered as suitable
alternatives for HRT.
Physiologically, while ERα is associated with the promotion
of cell proliferation that contributes to the occurrence of breast
and endometrial cancer, several studies have shown that ERβ
inhibits ERα-dependent cell proliferation and could prevent
cancer development [15,22,37-43]. 17β-estradiol (E2) has
similar binding affinities for the two ER subtypes [44], and the
subtypes stimulate the transcription of both common and
distinct subsets of E2 target genes [13,17,39,45]. However, in
many cases the degree of activation via ERβ is lower [44],
despite the high ligand independent transcriptional activity of
this subtype [46,47]. In light of the above, it has been
suggested that the development of ER subtype specific ligands
may herald the arrival of a new generation of estrogen
analogues that may present a novel treatment for post-
menopausal symptoms, which in addition, may prevent or
decrease the occurrence of breast cancer [44,48,49]. An ideal
or “designer” estrogen analogue or selective estrogen receptor
subtype modulator (SERSM) has been postulated that would
have the following attributes: act as an ERα selective
antagonist [50], down-regulate ERα protein levels [50,51],
selectively activate ERβ transcriptional pathways [15,19,24,43],
and display anti-inflammatory properties by inhibiting
transcription of pro-inflammatory genes to prevent the
occurrence of post-menopausal osteoporosis [15,52]. Current
examples of subtype specific ligands are, methyl-piperidino-
pyrazole (MPP) (ERα antagonist) [53,54], diarylpropionitrile
(DPN) (ERβ agonist) [55], ERB-041 (ERβ agonist) [56,57],
liqueritigenin (ERβ agonist) [19], isolated from the plant extract
MF101 (ERβ agonist) [24]. Phytoestrogens have been referred
to as natural SERMs and can be both estrogenic as well as
antiestrogenic [58-60]. Furthermore, although evidence in the
literature shows that phytoestrogens can bind to both ER
subtypes, they generally have a higher affinity for the ERβ
subtype [61-63] as well as a higher transcriptional potency and
efficacy via ERβ [63]. Despite conflicting evidence regarding
doses of phytoestrogens and breast cancer risk [64,65],
generally, findings have pointed the search in the direction of
phytoestrogens and focused attention on phytoestrogen rich
food sources as a possible source of the ideal SERSM.
One such source may be Cyclopia (family: Fabaceae), an
indigenous fynbos plant from the Western Cape province of
South Africa [66,67]. Traditionally, the “fermented” (oxidized)
form of Cyclopia, has been consumed as a fragrant, caffeine
free honeybush tea beverage with the “unfermented” form
being introduced to the commercial market more recently
[63,67,68]. Studies that investigated the chemical composition
of Cyclopia have shown that phenolic compounds with
estrogenic activity, for example luteolin, eriodictyol, naringenin,
and formononetin, are present in various species of Cyclopia
[63,68-72]. Furthermore, although dried methanol extracts
(DMEs) from plant material of two species of Cyclopia, C.
genistoides and C. subternata, have been shown to bind to the
ERs and are able to transactivate an ERE-containing promoter
reporter construct [62,63,68], only the extract from C.
genistoides was investigated for ER subtype specificity and
found to transactivate only through ERβ, despite binding to
both subtypes [62,63]. In addition, studies by Verhoog et al.
[63] and Mfenyana et al. [68] showed that although extracts of
Cyclopia are able to induce proliferation of the ERα and ERβ
positive MCF-7 BUS cells, they antagonise E2 induced cell
proliferation.
The current study was prompted by the findings of Verhoog
et al. [62,63] that the Cyclopia extract, P104, although binding
to both receptors and with a much higher affinity for ERα, was
able to activate an ERE-containing promoter reporter construct
only via ERβ. As the possibility of ERα antagonism by Cyclopia
extracts had not been addressed in previous studies it
appeared essential to evaluate ERα antagonism while also re-
evaluating ERβ agonism. The combination of ERα antagonism
and ERβ agonism may be especially relevant for the
chemoprevention of breast cancer as ER antagonism serves
as the basis of current chemo-preventative agents
[29,31,32,73,74], while ERβ specific agonists have recently
been identified as having potential for the chemoprevention of
breast cancer [19,22]. In addition, this combination might be
advantageous for the treatment of menopausal symptoms as
an ERβ agonist has been shown to alleviate both hot flashes
and the surge of inflammation related diseases during
menopause [24,52], while an ERα antagonist would not result
in hyperplasia of the uterus, commonly associated with ERα
agonists [15,52]. Thus, in this study, we evaluate the potential
of several extracts of Cyclopia to act as ERα antagonists and
ERβ agonists and demonstrate that all extracts display ERα
antagonism, while two also display ERβ agonism. In addition,
all extracts antagonise E2-induced MCF-7BUS cell proliferation,
one extract displays anti-inflammatory activity, and the two
tested extracts do not stimulate uterine growth. These results
suggest that the Cyclopia extracts, which display ERα
antagonism and ERβ agonism, have positive attributes that
could possibly be further exploited for the development of safer
drugs for the treatment or prevention of osteoporosis or pre-
menopausal symptoms.
Material and Methods
Ethics statement
Animal care and experimental procedures were conducted
with strict adherence to the accepted standards for the use of
animals in research and teaching as reflected in the South
African National Standards 10386: 2008. Stellenbosch
University ethics committee approved this study (ethical
approval reference: 11NB_LOU01).
Test Compounds
17β-Estradiol (E2), genistein, luteolin, enterodiol, phorbol 12-
myristate 13-acetate (PMA) and fulvestrant (ICI 182,780) were
obtained from Sigma-Aldrich®, South Africa, and coumestrol
was obtained from Fluka™ Analytical, Sigma-Aldrich®, South
Africa. The Cyclopia extracts used for in vitro studies, P104
[62], SM6Met [68] and cup-of-tea [68], were previously
prepared, while for in vivo studies new SM6Met and cup-of-tea
extracts were prepared as previously described [68]. E2,
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genistein, luteolin, enterodiol, coumestrol and Cyclopia extract
stock solutions were prepared in dimethylsulfoxide (DMSO).
High-performance liquid chromatography (HPLC)
analysis of C. subternata extracts
The newly prepared SM6Met and cup-of-tea extracts were
analyzed using HPLC. Extracts and stock solutions of
standards were prepared in DMSO and aliquots frozen at
-20°C until needed for analysis. For experimental analysis
ascorbic acid was added to defrosted standards and extracts to
a final concentration of 9.8 mg/ml. The mixtures were then
filtered using Millex-HV syringe filters (Millipore) with a 0.22 µm
pore size.
Analyses were performed on an Agilent 1200 HPLC
consisting of an in line degasser, diode-array detection (DAD),
column oven, autosampler and quaternary pump, controlled by
Chemstation software (Agilent Technologies, Santa Clara, CA).
The HPLC method previously described by De Beer et al. [75]
was used to quantify the major phenolic compounds in C.
subternata extracts: A Gemini-NX C18 (150 × 4.6 mm; 3 μm;
110 Å) column was used in conjunction with 2% acetic acid (A)
and acetonitrile (B) as mobile phases. Injection volumes
ranged from 10-20 µl for standards and 5-50 µl for the extracts.
Separation was performed at a flow rate of 1 ml/min with the
following mobile phase gradient: 0-2 min (8% B), 2-27 min
(8-38% B), 27-28 min (38-50% B), 28-29 min (50% B), 29-30
min (50-8% B), 30-40 min (8% B); at a temperature of 30°C.
The dihyrochalcones, flavanones and benzophenones were
quantified at 288 nm, whereas the xanthones, flavones and
phenolic acids were quantified at 320 nm. A calibration curve
consisting of seven points was set up for all the available
standards (mangiferin (Sigma-Aldrich®, South Africa),
isomangiferin (Chemos GmbH, Germany), luteolin
(Extrasynthese, France), eriocitrin (Extrasynthese, France),
hesperidin (Sigma-Aldrich®, South Africa), protocatechuic acid
(Fluka™ Analytical, Sigma-Aldrich®, South Africa)) and also
standards needed to calculate equivalent values (aspalathin
(kind gift from Prof. Gelderblom, PROMEC unit, Medical
Research Council, Tygerberg, South Africa), apigenin (Fluka™
Analytical, Sigma-Aldrich®, South Africa), and nothofagin (kind
gift from Prof. Gelderblom, PROMEC unit, Medical Research
Council, Tygerberg, South Africa)). Iriflophenone-3-C-β-
glucoside and iriflophenone-di-O,C-hexoside was quantified
using iriflophenone-3-C-glucoside isolated from C. genistoides
(personal communication from Dr. D. de Beer). Scolymoside
and vicenin-2 were expressed as luteolin and apigenin
equivalents, respectively, as no authentic reference standards
were available for these compounds. Also phloretin-3',5'-di-C-
glucoside was expressed in terms of nothofagin (3-
hydroxyphloretin-3'-C-glucoside) equivalents.
Cell Culture
COS-1, African green monkey kidney fibroblast cells (ATCC,
United States of America), and MCF-7BUS human breast
cancer cells [76] (a kind gift from A. Soto, Tufts University,
Boston, Massachusetts, United States of America) were
maintained in high glucose (4.5 g/L) Dulbecco’s modified
eagle’s medium (DMEM) (Sigma-Aldrich®) supplemented with
10% FCS (Highveld Biologicals, South Africa), 100 IU/ml
penicillin and 100 µg/ml streptomycin (Gibco, Invitrogen™,
South Africa), 2mM glutamine (Merck), 44mM sodium-
bicarbonate (Gibco), 1mM sodiumpyruvate (Gibco, Invitrogen
Corporation), and 0.1mM non-essential amino acids (Gibco).
All cells were maintained in a humidified cell incubator, set at
97% relative humidity and 5% CO2 at 37°C. For the cell
proliferation assays (MTT assay) MCF-7BUS cells were
withdrawn from 100 IU/ml penicillin and 100µg/ml streptomycin
for seven days prior to use.
MTT assay
On day one MCF-7BUS cells were seeded into 96-well tissue
culture plates at a concentration of 2500 cells/well and allowed
24 hours to settle. The next day cells were washed with 200 µl/
well pre-warmed PBS and the medium was changed to DMEM
without phenol red supplemented with 5% charcoal treated
FCS (Highveld Biologicals, South Africa) and incubated for 24
hours. After incubation the cells were treated for 48 hours with
increasing concentrations test compounds and Cyclopia
extracts in the presence or absence of 10-9M E2 where after the
colorimetric MTT (3-(4,5- dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) assay, adapted from Verhoog et
al. [63] and Mfenyana et al. [68], was performed. Briefly, the
MTT assay entails that 4 hours before the end of the incubation
period the assay medium is changed to 150 µl DMEM without
phenol red, but supplemented with 5% charcoal stripped FCS,
and 50 µL of MTT (methylthiazolyldiphenyl-tetrazolium )
(Sigma-Aldrich®) solution (5 mg/ml) is added to each well. Cells
are then incubated for four hours at 37°C, the medium
removed, and 200 µL of solubilisation solution (DMSO) added
to each well. The plate is then covered with foil, shaken at
room temperature for 5 min, and the absorbance read at 550
nm on a BioTek® PowerWave 340 spectrophotometer. All
assays included a negative solvent control, which consisted of
0.1% (v/v) DMSO only. Results are expressed as fold induction
relative to solvent.
Promoter reporter studies
MCF-7BUS and COS-1 cells were seeded in sterile 10 cm
tissue culture plates at a concentration of 2 x 106 cells/plate
and allowed 24 hours to settle. On day two the cells were
rinsed once with sterile phosphate buffered saline (PBS) (pre-
warmed to 37°C), medium changed to DMEM without phenol
red supplemented with 10% charcoal treated FCS and 1%
penicillin and streptomycin mixture, and cells were transfected.
Plasmids.  Human (h) ERα (pSG5-hERα [77]) and ERβ
(pSG5-hERβ [78]) expression plasmids were kind gifts from F.
Gannon (European Molecular Biology Laboratory, Heidelberg,
Germany). The ERE-containing promoter reporter construct
(ERE.vit2.luc) was a kind gift from K. Korach, National Institute
of Environmental Health Science, U.S. [79] and the NFκB-
containing promoter reporter construct (p(IL6κB)350hu.IL6Pluc
+ [80]) was a kind gift from G. Haegeman, University of Ghent,
Ghent, Belgium. pGL2-Basic (Promega Corporation, Madison,
Wisconsin, U.S.A.) was used as an empty vector.
Transactivation.  To test transactivation through ERα
COS-1 cells were transfected with 150 ng hERα and 6000 ng
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of an ERE-containing promoter reporter construct. To test
transactivation through ERβ COS-1 cells were transfected with
150 ng hERβ, 3000 ng of an ERE-containing promoter reporter
construct, and 3000 ng empty vector. MCF-7 BUS cells (which
contain endogenous hERα and hERβ) were transfected with
3000 ng of an ERE-containing promoter reporter construct and
3000 ng empty vector. The amount of promoter reporter
construct for each test model that was selected was
determined by the highest E2 induction achieved (Figure S1).
Transrepression.  To test transrepression through ERα
COS-1 cells were transfected with 150 ng hERα, 1500 ng of an
NFκB-containing promoter reporter construct and 4500 ng
empty vector. To test transrepression through ERβ COS-1 cells
were transfected with 150 ng hERβ, 4500 ng of an NFκB-
containing promoter reporter construct and 1500 ng empty
vector. MCF-7BUS cells (which contain endogenous hERα and
hERβ) were transfected with 6000 ng of an NFκB-containing
promoter reporter construct. The amount of promoter reporter
construct for each test model that was selected was
determined by the most effective E2 repression of PMA
induction achieved (Figure S2)
All transfections were performed using FuGENETM 6
transfection reagent (Roche Applied Science, South Africa) as
described by the manufacturer. Cells were left for 24 hours,
replated in sterile 24-well tissue culture plates at a
concentration of 5 x 104 cells/well and allowed 24 hours to
settle. Cells were treated for 24 hours with test compounds and
Cyclopia extracts and lysed overnight with 50 µl lysis buffer
[0.2% (vol/vol) Triton, 10% (vol/vol) glycerol, 2.8% (vol/vol)
Tris-phosphate-EDTA, and 1.44 mM EDTA] per well at -20 °C.
Luciferase activity was determined using the luciferase assay
kit (Promega Corporation, Anatech, South Africa) according to
the manufacturer’s instructions and normalized for protein
content (Bradford assay [81]). Results are expressed as fold
induction relative to solvent.
Western Blot
Cell lysates from COS-1 cells transfected with either ERα
(150 ng hERα/10 cm plate) or ERβ (150 ng hERβ/10 cm plate)
and MCF-7BUS cells were prepared by adding lysis buffer A
(10mM Hepes pH 7.5 (Gibco, Invitrogen Corporation), 1.5mM
MgCl2, 10mM KCl, 0.1% NP-40 (Roche Applied Science) and
Complete Mini protease inhibitor cocktail (Roche Applied
Science), shaking on ice for 15 min and frozen overnight at
-20°C.
On thawing, lysate were transferred to 1.5ml Eppendorf
tubes on ice, centrifuged for 10 min at 12 000 x g at 4°C and
the cleared lysate was transferred to 1.5ml Eppendorf tubes on
ice, alliquoted and stored at -20°C until assayed. Lysates (20µl)
were separated on a 10% SDS-PAGE gel. Following
electrophoresis, proteins were electro-blotted and transferred
to a Hybond-ECL nitrocellulose membrane (Amersham
Biosciences, South Africa), which was probed for ERα (diluted
1:500), ERβ (1:250) and GAPDH (1:500). Proteins were
visualized using HRP labeled anti-rabbit antibody for ERα
(1:2500) and ERβ (1:1000), or HRP labeled anti-mouse
antibody for GAPDH (1:5000), and ECL Western blotting
detection reagents (Pierce®, Thermo Fisher Scientific Inc.,
U.S.A.) and medical x-ray film (Axim (PTY) LTD., South Africa).
All antibodies, primary [ERα (HC-20), cat# sc-543, ERβ
(H-150), cat# sc-8974, and GAPDH (0411), cat# sc-47724] and
secondary (anti-rabbit, cat# sc-2005, and anti-mouse, cat#
sc-2030), were purchased from Santa Cruz Biotechnology,
Inc., U.S.A.
Animal care
Immature female Wistar rats were obtained from the
Stellenbosch University, South Africa, breeding unit and were
received as weanlings on postnatal day 18. The animals had
free access to standard rat feed (Pure Harvest Rat Feed,
Afresh Vention (PTY) Ltd, South Africa) and drinking water.
The animals were housed in a 12 hour light-dark cycle at a
constant temperature of 20 °C in EHRET individually ventilated
cages (EHRET, Emmedingen, Germany). The animals were
allowed at least 24 hours to acclimatize before the onset of
experimental procedures.
Immature rat uterotrophic assay
The immature rat uterotrophic assay was performed
according to methods previously described by Kanno et al. [82]
and de Lima et al. [83]. Immature Wistar rats (21 days) were
randomly assigned to groups (n=10) and treated daily with E2,
genistein, Cyclopia extracts, or vehicle control (sterile PBS) by
oral gavage for three consecutive days. The dose volume was
200 μl/day. The test compounds were suspended in sterile
PBS and the solution was kept homogenous by stirring before
administration. General health, vaginal opening, and body
weight was monitored daily and recorded. On day four,
approximately 24 hours after last dose, animals were weighed
and sacrificed by administration of a high dose of Isoflurane (2-
chloro-2-(difluoromethoxy)-1,1 1-trifluoro-ethane), (Safeline
pharamceuticals Pty (Ltd)). Livers were removed and weighed.
Uteri were removed, cleaned of excess fat, photographed,
weighed, pierced to remove luminal fluids, and blotted uterine
weights were obtained immediately.
Evaluation/Monitoring of vaginal opening of Wistar rats
for extended period
Immature Wistar rats (21 days) were randomly assigned to
groups (n=10) and treated daily with E2, Cyclopia extracts, or
vehicle control (sterile PBS) by oral gavage for 30 consecutive
days. The dose volume had to be increased gradually from 200
μl/day to 400 μl/day as animals increased in body weight. The
test compounds were suspended in sterile PBS and the
solution was kept homogenous by stirring before
administration. General health, vaginal opening, and body
weight was monitored daily and recorded. On day 30 animals
were weighed and sacrificed by administration of a high dose
of Isoflurane.
Data manipulation and statistical analysis
The GraphPad Prism® version 5.10 for Windows (GraphPad
Software) was used for graphical representations and statistical
analysis. One-way ANOVA and Dunnett’s post-test comparing
all columns to the solvent control were used for statistical
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analysis and significance is displayed on the graphs. For all
experiments the error bars represent the SEM of at least two
independent experimental repeats, except for in vivo studies
where the error bars represent the SEM of the number of
animals used.
Results
HPLC analyses of extracts of Cyclopia
New SM6Met and cup-of-tea extracts were prepared from
the same harvesting of C. subternata previously used to
prepare these extracts [68]. HPLC analysis was performed on
these newly prepared SM6Met and cup-of-tea extracts (Table
1). Prior HPLC results of previously prepared P104 [63] and
SM6Met [68] extracts are also shown in Table 1. The results
indicate the presence of the xanthones, mangiferin and
isomangiferin, the flavones, scolymoside, luteolin, and
vicenin-2, the flavanones, eriocitin and hesperidin, the
dihydrochalcones, phloretin-3,5-di-C-glucoside and aspalathin,
the benzophenones, iriflophenone-3-C-β-glucoside and
iriflophenone-di-O,C-hexoside, and the phenolic carboxylic
acid, protocatechuic acid. P104, a DME from C. genistoides,
contained more mangiferin and isomangiferin than SM6Met, a
DME from C. subternata, while, the cup-of-tea extract from the
same species contained the least. Luteolin was present in all of
the extracts, albeit at small amounts, with the P104 extract
containing the largest amount, followed by the SM6Met
extracts, and with the cup-of-tea extract containing the least.
The luteolin rutinoside, scolymoside, was not evaluated in
P104. The DMEs of C. subternata contained more
scolymoside, eriocitrin, hesperidin, and phloretin-3,5-di-C-
glucoside than the cup-of-tea extract. The newly prepared
DME, SM6Met, contained higher amounts than the cup-of-tea
extract of compounds not previously tested for, namely,
iriflophenone-3-C-β-glucoside, iriflophenone-di-O,C-hexoside,
aspalathin, vicenin-2, and protocatechuic acid. In general the
DMEs contained higher concentrations of the polyphenols
quantified (Table 1) than the water extract.
Methanol extracts of Cyclopia act as agonists of ERβ,
while all extracts antagonize E2-induced activation via
ERα
To evaluate ERα antagonism while also re-evaluating ERβ
agonism COS-1 cells were transiently transfected with either
ERα (Figures 1 A, C) or ERβ (Figures 1 B, D) and an ERE-
containing promoter reporter construct. Agonism was tested in
the absence (Figures 1 A, B) and antagonism in the presence
(Figures 1 C, D) of 10-9 M E2. Three Cyclopia extracts, from two
species, C. genistoides and C. subternata, were tested. Two
were methanol extracts, P104 and SM6Met, and one was a
water extract, cup-of-tea. In addition we investigated an
example from each of the major classes of phytoestrogens:
genistein, a well-studied isoflavone, enterodiol, a lignin, and
coumestrol, a coumestan [84,85]. Luteolin, an estrogenic
polyphenol [71], was also included as it was found be present
in all of the Cyclopia extracts (Table 1), while E2 represents the
major endogenous estrogen [86,87].
E2 induced ERα mediated transactivation in a dose
dependent manner with significant induction at two
concentrations of E2, 10-9 M (2.7 x 10-4 μg/ml) (2.5 ± 0.5 fold)
and 9.8 µg/ml (3.6 x 10-5 M) (3.9 ± 0.7 fold), but not at the
lowest concentration of 10-11 M (2.7 x 10-6 µg/ml) (Figure 1A).
The same trend was seen for ERβ (2.5 ± 0.5 fold at 10-9 M and
2.7 ± 0.4 fold at 9.8μg/ml) (Figure 1B), although at the highest
concentration of E2 higher induction was observed via ERα
than via ERβ (3.9 ± 0.7 vs. 2.7 ± 0.4 fold). Although the 9.8
μg/ml E2 represents a supra-physiological concentration the
10-11 M and 10-9 M E2 concentrations reflect the pre- and post-
menopausal levels of E2 respectively [88]. At the concentration
of 9.8 µg/ml, genistein (3.6 x 10-5 M), luteolin (3.4 x 10-5 M), and
coumestrol (3.7 x 10-5 M) significantly activated gene
transcription through both of the ER subtypes (Figures 1A, B).
Table 1. Major polyphenols present in previously and newly
prepared extracts of Cyclopia as determined by HPLC.
 Extract
 Previously prepared Newly prepared
Polyphenol [% of dry
extract (g/100g dry
extract)]
P104 [63]
C.genistoides
SM6Met [68]
C.subternata
SM6Met
C.subternata
Cup-of-tea
C.subternata
Mangiferin 3.606 1.850 1.899 1.000
Isomangiferin 5.094 0.750 0.645 0.420
Luteolin 0.096 0.040 0.040 0.018
Scolymoside
(luteolin-7-O-
rutinoside)
nta 1.820c 1.289 0.876
Vicenin-2
(apigenin-6,8-di-C-
glucoside)
nt nt 0.089 0.065
Eriocitrin
(eriodictyol-7-O-
rutinoside)
ndb 1.250 0.846 0.600
Hesperidin
(hesperitin-7-O-
rutinoside)
nt 1.870 2.049 0.935
Phloretin-3,5-di-C-
glucoside nt 1.270
d 1.278 0.939
Aspalathin (3-
hydroxyphloretin-3',
5'-di-C-hexoside)
nt nt 0.700 0.582
Iriflophenone-3-C-β-
glucoside nt nt 0.669 0.590
Iriflophenone-di-O,C-
hexoside nt nt 0.958 0.896
Protocatechuic acid nt nt 0.113 0.082
aNot tested
bNot detected
cPreviously “Unknown 1” was quantified as luteolin equivalents as it appeared to
be a flavone.
dPreviously “Unknown 2” was quantified as hesperidin equivalents as it appeared
to be a flavanone.
doi: 10.1371/journal.pone.0079223.t001
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Enterodiol, however, could not significantly activate gene
transcription through either of the subtypes at the concentration
of 9.8 µg/ml (3.2 x 10-5 M) (Figures 1A, B). None of the
Cyclopia extracts were able to induce activation through ERα
(Figure 1A), but both the methanol extracts, P104 and
SM6Met, were able to significantly activate transcription
through ERβ (2.4 ± 0.4 and 2.5 ± 0.3 fold, respectively).
To address antagonism, transactivation in the presence of
10-9 M E2 was evaluated (Figure 1C and D). The phenolic
compounds, genistein, luteolin, and coumestrol were not
Figure 1.  Evaluation of ER subtype specific agonism and antagonism of transactivation of an ERE-containing promoter
reporter construct in COS-1 cells.  COS-1 cells were transfected with either (A and C) pSG5-hERα or (B and D) pSG5-hERβ and
ERE.vit2.luc and treated for 24 hours with a series of test compounds or extracts. To test agonism cells were treated with test
compounds or extracts alone, (A and B), while, to test for antagonism cells were treated with test compounds or extracts in the
presence of 10-9M E2 (C and D). Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all
columns to the solvent control (*, P<0.05; **, P<0.01; ***, P<0.001). The dotted line through the bars represents the values for
solvent control. Average ± SEM is of four independent experiments done in triplicate.
doi: 10.1371/journal.pone.0079223.g001
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antagonists but had an additive effect on E2-induced activation
via both receptor subtypes (Figures 1C and D), confirming their
agonism through both subtypes (Figure 1A and B). Enterodiol
in contrast, however, only displays ERα antagonism (0.7 ± 0.1
fold vs. E2 activation set as 1) (Figure 1C). All of the Cyclopia
extracts significantly antagonized ERα mediated E2-induction
(P104, 0.7 ± 0.1, SM6Met, 0.7 ± 0.1, and cup-of-tea, 0.6 ± 0.1
fold), however, only P104 had an additive effect on the E2-
induced activation through ERβ (Figure 1D). In conclusion, the
methanol extracts of Cyclopia are ERβ agonists and all extracts
are ERα antagonists.
In MCF-7BUS cells expressing both ER subtypes all
extracts of Cyclopia transactivate an ERE-driven
promoter reporter construct
Most tissues affected by menopause and/or implicated in
HRT side effects, such as uterus, bone, and breast, contain
both ER subtypes [89]. Thus, having shown that methanol
extracts of Cyclopia are ERβ agonists and all extracts are ERα
antagonists in a system where the ER subtypes were
evaluated separately, we were interested in investigating the
transactivation potential of Cyclopia extracts in a system where
both subtypes are present.
MCF-7BUS cells, containing both ERα and ERβ (Figure 2A),
were transfected with an ERE-containing promoter reporter
construct and both agonism (Figure 2B) and antagonism
(Figure 2C) were tested. Although strong transactivation was
seen with E2, none of the polyphenols on their own were able
to significantly activate gene transcription in this system where
both ER subtypes are present (Figure 2B), despite the fact that
these polyphenols transactivate when the ER subtypes function
in isolation (Figure 1A and B). Furthermore, most of the
polyphenols, excluding coumestrol, antagonized E2 induction
when both ER subtypes are together (Figure 2C), whereas
when the subtypes were expressed separately only enterodiol
showed ERα antagonism (Figure 1C). In contrast to the
polyphenols, the extracts of Cyclopia, P104 (3.4 ± 0.5 fold),
cup-of-tea (3.4 ± 0.5 fold) and, SM6Met (3.5 ± 0.6 fold), were
able to activate transcription to a similar extent as 10-9 M E2
(3.8 ± 0.3 fold) (Figure 2B). These results, together with the
fact that the Cyclopia extracts did not antagonize E2 induction
(Figure 2C), suggests that when both ER subtypes are co-
expressed the Cyclopia extracts act as agonists, whereas
when the ER subtypes are expressed separately they only act
as agonists through ERβ and antagonize ERα induction.
An extract of C. genistoides represses NFκB activation via
ERα and ERβ whereas the extracts of C. subternata are ERβ
antagonists.
The decline in estrogen levels during menopause leads to a
surge in the occurrence of inflammatory disorders [52,90-92].
Furthermore, NFκB, a pro-inflammatory transcription factor, is
involved in the development of breast cancer [93-95]. Taking
this into account we wanted to evaluate the ability of Cyclopia
extracts to repress the activation of an NFκB-containing
promoter reporter construct by transfecting COS-1 cells with
said construct and either ERα (Figures 3A, C, E) or ERβ
(Figures 3B, D, F). In addition, this system would provide
information concerning the behavior of Cyclopia extracts in a
transrepression model. Agonism was tested in the absence
(Figures 3A, B) and antagonism (Figures 3C, D) in the
presence of 10-9 M E2.
PMA (phorbol 12-myristate 13-acetate, an activator of NFκB
driven gene expression [96,97]) activation of the NFκB-
containing construct was repressed by E2 via both receptor
subtypes (Figure 3A and B) with a more pronounced
repression through ERα (38.6% vs. 27.2%). Like E2, all of the
polyphenols, as well as P104 (C. genistoides extract), acted as
ERα agonists by repressing PMA activation (genistein 52.1%,
luteolin 50.6%, enterodiol 57.4%, coumestrol 61.8%, and P104
59.2%) (Figure 3A). Furthermore, genistein (34.8% repression)
and P104 (40.7% repression), like E2, also displayed significant
ERβ agonism (Figure 3B). Therefore, in our transrepression
model P104 is not an ERβ selective agonist, but displays
agonism via both subtypes. The water extract of C. subternata,
cup-of-tea, was unable to repress PMA induction through either
ERα or ERβ (Figures 3A, B) while the methanol extract,
SM6Met, also unable to repress PMA induction through either
subtype, significantly added to the activation observed with
PMA alone via ERα (5.1 ± 0.5 vs. 3.5 ± 0.5) (Figure 3A, B).
Antagonism was evaluated in the presence of 10-9 M E2 and
only genistein (Figure 3C) had a significant effect via ERα by
antagonizing E2 repression of PMA activation. The
polyphenols, luteolin, enterodiol, and coumestrol, but not
genistein, however, antagonized E2 repression of PMA
activation via ERβ (Figure 3D). Although none of the extracts
displayed significant antagonism of ERα, the extracts of C.
subternata displayed ERβ antagonism (Figure 3D).
The result for SM6Met in Figure 3A prompted us to
investigate whether this effect was via ERα or if SM6Met is
able to activate the NFκB-containing construct through another
mechanism of action. Therefore, we repeated the experiment,
for both receptor subtypes, with SM6Met, as well as P104, in
the presence and absence of an ER antagonist, ICI 182,780
(Figures 3E, F). The observed repression of PMA activation by
E2 and P104 via ERα and ERβ is abolished by ICI (Figure 3E,
F) and thus, the observed repression is indeed via the ER.
SM6Met, like ICI, increases PMA activation through ERα
(Figure 3E) and both have no significant effect on PMA
activation via ERβ (Figure 3F). Furthermore, the increased
transactivation observed with SM6Met in Figure 3A may be
attributed to residual E2 remaining after stripping of FCS, as
suggested by others [22], which would further support the
contention that SM6Met is behaving as an ERα antagonist. In
conclusion then the results suggest that for our transrepression
model the methanol extract of C. genistoides (P104) is
behaving like an ERα and ERβ agonist, while the methanol
extract of C. subternata (SM6Met) is an ERα antagonist in the
absence of E2, and an ERβ antagonist in the presence of E2.
In MCF-7BUS cells expressing both ER subtypes all extracts
are agonists, while the water extract of C. subternata also
displays antagonistic activity.
As we have shown that P104 is an ER agonist and SM6Met
is an ER antagonist in a transrepression model where the ER
subtypes function in isolation (Figure 3), we wanted to test the
effect of these extracts in a model where both subtypes are
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present as most tissues affected by menopause and/or
implicated in HRT side effects contain both subtypes.
MCF-7BUS cells were transfected with an NFκB-containing
promoter reporter construct and both agonism (Figure 4A) and
antagonism (Figure 4 B) evaluated. Strong repression was
observed with E2, the polyphenols, and P104 when both
subtypes are present (Figure 4A), which correlates with what
was observed previously for ERα alone (Figure 3A). However,
for ERβ alone (Figure 3B), significant repression was
previously seen only with E2, genistein, and P104 but not with
luteolin, enterodiol, and coumestrol. Unlike previous results,
SM6Met behaved differently when subtypes were co-
expressed than when the subtypes were expressed separately.
It displayed agonism when subtypes are expressed together
(Figure 4A) while displaying antagonism when expressed
separately (Figure 3A and D). Similarly, where no agonist
activity via either subtype alone was observed previously, the
cup-of-tea extract was able to change its behavior when both
subtypes are present by displaying ER agonism. Furthermore,
antagonism in the presence of both subtypes was only seen
with the cup-of-tea extract (Figure 4B), while the subtype
specific antagonism of genistein, luteolin, enterodiol,
coumestrol, and SM6Met (Figures 3C, D) is abrogated in the
presence of both subtypes. Taken together, in a
transrepression model, the DME of C. genistoides, P104, is an
ER agonist in all models (Figures 3A, B, and 4A), the DME of
C. subternata, SM6Met, is an ERβ antagonist in the presence
of E2 (Figure 3D), an ERα antagonist in the absence of E2
(Figure 3A, E), and an agonist in the presence of both ER
subtypes (Figure 4A), while the water extract of C. subternata,
cup-of-tea, is an ERβ antagonist (Figure 3D) and an ER
agonist/antagonist (Figures 4A, B) in the presence of both
subtypes. This differential behavior of the Cyclopia extracts in
the transrepression model contrasts to similar behavior by the
extracts in the transactivation model where all extracts
displayed antagonism through ERα (Figure 1) alone, while
displaying agonism to ERβ (Figure 1) alone or when both
subtypes are expressed (Figure 2).
Figure 2.  Evaluation of transactivation of an ERE-containing promoter reporter construct in MCF-7BUS cells expressing
both ERα and ERβ.  MCF-7BUS cells, with endogenous ERα and ERβ (A), were transfected with ERE.vit2.luc and treated for 24
hours with a series of test compounds or extracts. To test agonism cells were treated with test compounds or extracts alone (B),
while, to test for antagonism cells were treated with test compounds or extracts in the presence of 10-9M E2 (C). Statistical analysis
was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the solvent control (*, P<0.05; **, P<0.01; ***,
P<0.001). The dotted line through the bars represents the values for solvent control. Average ± SEM is of three independent
experiments done in triplicate.
doi: 10.1371/journal.pone.0079223.g002
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Figure 3.  Evaluation of ER subtype specific agonism and antagonism of an NFκB-containing promoter reporter construct
in COS-1 cells.  COS-1 cells were transfected with either (A, C, and E) pSG5-hERα or (B, D, and F) pSG5-hERβ and
p(IL6kB)350hu.IL6Pluc+ and treated for 24 hours with a series of test compounds or extracts. To test agonism cells were treated
with test compounds or extracts alone, (A and B), while, to test antagonism cells were treated with test compounds or extracts in the
presence of 10-9 M E2 (C and D). To ascribe the observed effect to the ER we treated cells with P104 and SM6Met in the absence or
presence of the ER antagonist ICI 182,870 (E and F). Statistical analysis was done using One-way ANOVA with Dunnett’s post-test
comparing all columns to either (A, B, E, and F) 10ng/ml PMA or (C and D) 10ng/ml PMA + 10-9M E2 (*, P<0.05; **, P<0.01; ***,
P<0.001). The dotted lines through the bars represent the values for either (A, B, E, and F) solvent control, 10ng/ml PMA, or
10ng/ml PMA + 10-9M E2 or (C and D) 10ng/ml PMA + 10-9M E2. Average ± SEM is of three independent experiments done in
triplicate.
doi: 10.1371/journal.pone.0079223.g003
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Cyclopia extracts weakly induce proliferation of breast
cancer cells but antagonizes E2-induced breast cancer
cell proliferation
Having shown that Cyclopia extracts can modulate both
transactivation and transrepression in the presence of both ER
subtypes and when the subtypes are expressed alone, we
wanted to re-evaluate agonism of P104 [63], SM6Met and cup-
of-tea [68] (Figure 5) and antagonism of P104 [63] (Figure 6)
and for the first time evaluate antagonism of SM6Met and cup-
of-tea (Figure 6) on MCF-7BUS breast cancer cell proliferation.
Cell proliferation in MCF-7BUS cells constitutes an integrated
model where not only the ER subtypes are co-expressed, but
both transactivation and transrepression of endogenous genes
contribute towards the final phenotype, whether it is
proliferative or anti-proliferative [39,98-100].
The MTT cell proliferation assay using MCF-7BUS cells was
used to address agonism (Figure 5A-H). Estrogen induced cell
proliferation at a wide range of concentrations (10-6 M to 10-10
M) with the highest efficacy (2.1 ± 0.1 fold) observed at 10-9 M
E2 (2.7 x 10-4 μg/ml) (Figure 5A). Like E2, all of the polyphenols
were also able to induce cell proliferation, but not to the same
extent as E2, with a maximum efficacy of: genistein, 1.5 ± 0.1
fold at 10-9 M (2.7 x 10-4 μg/ml) (Figure 5B), luteolin, 1.5 ± 0.1
fold at 10-5 M (2.7 μg/ml) (Figure 5C), coumestrol, 1.6 ± 0.1 fold
at 10-6 M (3.0 x 10-1 μg/ml) (Figure 5D), and enterodiol, 1.3 ±
0.1 fold at 10-9 M (3.0 x 10-4 μg/ml) (Figure 5E). Similarly, all
three extracts of Cyclopia induced proliferation of cells with a
lower efficacy than E2 with maximum efficacies of 1.5 ± 0.2
(significantly different from E2), 1.3 ± 0.03 (significantly different
from E2), and 1.7 ± 0.2 (not significantly different from E2) fold
for 9.8 μg/ml of P104, cup-of-tea and SM6Met, respectively
(Figures 5F-H). The potencies, depicted by EC50 values on
graphs (Figures 5A-H), of the polyphenols, as well as of the
Cyclopia extracts, were lower than that of E2 with coumestrol,
P104, and SM6Met significantly lower and may be listed in
order of decreasing potency as follow: E2 > genistein >
enterodiol > luteolin > cup-of-tea > P104 > coumestrol >>
SM6Met.
To address antagonism (Figure 6A-G), increasing
concentrations of the polyphenols and Cyclopia extracts were
tested in the presence of 10-9 M E2 (highest efficacy, Figure
5A). Genistein (Figure 6A) and enterodiol (Figure 6D),
significantly repressed E2-induced cell proliferation (23.3% at
10-5 M (2.70 μg/ml) and 24.5% at 10-5 M (3.02 μg/ml),
respectively). Although, luteolin (Figure 6B) and coumestrol
(Figure 6C) displayed no significant antagonism, coumestrol
did have a significant additive effect (1.3 ± 0.1 fold) at 10-9 M
(2.96 x 10-4 μg/ml), suggesting agonism. Similarly, genistein, an
antagonist at high concentrations, also had a significant
additive effect (1.2 ± 0.1 fold) at the lower concentration of 10-8
M (2.70 x 10-3 μg/ml) (Figure 6A). All extracts of Cyclopia were
able to antagonize E2-induced cell proliferation, with P104
repressing 19.8% at 9.8 x 10-1 μg/ml, SM6Met 16.8% 9.8 x 10-4
Figure 4.  Evaluation of transrepression of an NFκB-containing promoter reporter construct in MCF-7BUS cells expressing
both ERα and ERβ.  MCF-7BUS cells were transfected with p(IL6kB)350hu.IL6Pluc+ and treated for 24 hours with a series of test
compounds or extracts. To test agonism cells were treated with test compounds or extracts alone, (A), while, to test for antagonism
cells were treated with test compounds or extracts in the presence of 10-9M E2 (B). Statistical analysis was done using One-way
ANOVA with Dunnett’s post-test comparing all columns to either (A) 10ng/ml PMA or (B) 10ng/ml PMA + 10-9M E2 (*, P<0.05; **,
P<0.01; ***, P<0.001). The dotted lines through the bars represent the values for either (A) solvent control, 10ng/ml PMA, or
10ng/ml PMA + 10-9M E2 or (B) 10ng/ml PMA + 10-9M E2. Average ± SEM is of three independent experiments done in triplicate.
doi: 10.1371/journal.pone.0079223.g004
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Figure 5.  Evaluation of agonism of proliferation, a more complex endpoint encompassing both transactivation and
transrepression in MCF-7BUS cells expressing both ERα and ERβ.  MCF-7 BUS cells were treated with increasing
concentrations of (A) E2, (B-E) polyphenols, and (F-H) Cyclopia extracts for 48 hours. After treatment the amount of living cells was
determined using a MTT assay. Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all
columns to the solvent control (*, P<0.05; **, P<0.01; ***, P<0.001) or to E2 for EC50 values (#, P<0.05; ##, P<0.01; ###, P<0.001).
The dotted line through the bars represents the values for solvent control. Average ± SEM is of two independent experiments done
in six replicates, except (A) where average ±SEM is of three independent experiments done in six replicates.
doi: 10.1371/journal.pone.0079223.g005
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Figure 6.  Evaluation of antagonism of proliferation, a more complex endpoint encompassing both transactivation and
transrepression in MCF-7BUS cells expressing both ERα and ERβ.  MCF-7 BUS cells were treated with increasing
concentrations of (A-D) polyphenols and (E-G) Cyclopia extracts for 48 hours in the presence of 10-9M E2. After treatment the
amount of living cells was determined using a MTT assay. Statistical analysis was done using One-way ANOVA with Dunnett’s post-
test comparing all columns to the solvent control (*, P<0.05; **, P<0.01; ***, P<0.001). The dotted line through the bars represents
the values for solvent control. Average ± SEM is of two independent experiments done in six replicates.
doi: 10.1371/journal.pone.0079223.g006
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 μg/ml, and cup-of-tea 15.6% repression at 9.8 x 10-4 μg/ml
(Figures 6E, F, G). Taken together, these results show that
although all extracts of Cyclopia induced cell proliferation, the
P104 and cup-of-tea extracts did so at a significantly lower
efficacy and the methanol extracts at a significantly lower
potency than E2, and that all extracts could antagonize E2-
induced cell proliferation.
SM6Met does not stimulate the growth of rat uteri,
antagonizes E2-induced uterine proliferation, and
delays vaginal opening
For the in vivo studies only extracts from C. subternata was
used as P104 plant material was not available in bulk. The
immature rat uterotrophic assay is used to determine the ability
of test compounds to stimulate ERα induced uterine growth as
ERβ is not highly expressed in the uterus [56,101] and also
allows for the detection of antiestrogens [102]. Rats were
administered E2, genistein, and the two C. subternata extracts,
SM6Met and cup-of-tea, via oral gavage and the effects on
uterine growth were evaluated (Figure 7A, B, and Figure S3).
Estrogen, as well as genistein, induced uterine growth (2.5 ±
0.2 and 2.0 ± 0.2 fold, respectively) (Figure 7). In contrast, the
extracts significantly reduced uterine weight relative to solvent
(Figure 7 and Figure S3). SM6Met also significantly repressed
E2-induced uterine growth by 33.0%, a result that is similar, but
less pronounced, than that seen with ICI 182,780 (59.7%
repression) (Figure 7) suggesting that the extracts behave as
antiestrogens in the uterus.
We also addressed body weight changes and toxicity (Figure
S4) and found that E2 significantly increased body weight,
whereas genistein significantly decreased body weight. The
extracts of Cyclopia and ICI 182,780, however, did not lead to
significant weight gain or loss as compared to solvent, except
for the animals treated with the highest concentrations
(2000mg/kg BW) of SM6Met and cup-of-tea extracts which
gained significantly less weight than the solvent treated
animals. With regards to toxicity, none of the treated animals
showed any significant changes in liver weight, except for a
decrease in liver weight in animals treated with 200mg/kg BW
SM6Met.
Furthermore, as another marker of estrogenic activity, albeit
a less sensitive marker [102], we also evaluated time of vaginal
opening over an extended period of daily treatments (Figure 8).
Estrogen led to premature vaginal opening when compared to
solvent (4.2 ± 0.4 vs. 14.3 ± 1.2 days). This correlates with the
observed increase in uterine weight in Figure 7. The
significantly delayed vaginal opening of SM6Met treated
animals (19.0 ± 1.3 days) also correlates with uterine weight
results in displaying antiestrogenic behavior. The significant
delay in vaginal opening was observed for all three of the
concentrations of SM6Met, however, although the cup-of-tea
extract showed a similar trend, it was not significant (Figure
S5).
To summarize, for the first time we show that the C.
subternata extracts are absorbed when administered orally and
elicit a biological effect in vivo. Specifically, Cyclopia extracts,
in contrast to E2 and genistein, did not induce uterine growth
and SM6Met antagonized E2-induced uterine growth.
Furthermore, the extracts also delayed vaginal opening in
contrast to E2. These results suggest that the Cyclopia extracts
display ERα antagonism in vivo by retarding uterine growth
[56,101].
Discussion
HRT in the form of estrogens provides relief from the
plethora of menopause associated symptoms [1]. Although
these estrogens provide relief from menopausal symptoms,
they introduced new HRT associated risks, including an
increased occurrence of breast cancer, heart disease, strokes,
and endometrial cancer [1,5,6,8]. These risks, and the
associated reluctance of usage, instigated the search for a new
generation of estrogen analogues that would provide the
benefits of estrogens without the associated risks. In addition, it
would be of great value if these new analogues display chemo-
preventative properties in breast and endometrial tissues
[9,10,29].
The search for new estrogen analogues heralded the era of
the SERMs. These SERMs would selectively modulate
estrogen receptors in different tissues, acting as antagonists in
the breast and uterus (chemo-preventative) and as agonists in
the bone (osteoporosis prevention). Tamoxifen, a first
generation SERM, provided the desired protective effect in the
breast [31,32] and raloxifene, a second generation SERM, had
protective properties in breast and bone tissues [26,27,103].
However, as these SERMS have been linked to the increased
occurrence of hot flashes and stimulated endometrial growth
(tamoxifen), the search continues [28,34,35]. Third generation
SERMs, such as lasoxifene and bazedoxifene, are currently in
development, but the focus has shifted to osteoporosis
treatment with protection against breast cancer as a beneficial
side effect [104-106].
Although SERM development continues there is increased
interest in SERSMs, analogues that can differentially modulate
specific ER subtypes. This was brought on by studies that have
shown that ERβ inhibits ERα dependent cell proliferation and
could prevent cancer development [15,22,37,40-43].
Phytoestrogens have been shown to be both estrogenic as well
as antiestrogenic and while they can bind to both ER subtypes,
they generally have a higher affinity for ERβ as well as a higher
transcriptional potency and efficacy via ERβ [61-63]. Thus,
phytoestrogen rich food sources have become important
potential resources of SERSMS.
The current study evaluated previously described extracts of
Cyclopia, a source of phytoestrogens, for ER agonism and/or
antagonism (summarized in Table S1). Specifically, we
evaluated the effect of Cyclopia extracts on transactivation and
transrepression in a model where ERα and ERβ were
expressed separately. This allows for the evaluation of the
modulation of ER subtype specific activity in two transcriptional
models: a classical ERE transactivation model and an NFκB
transrepression model. In the transactivation model the
methanol extracts, P104 and SM6Met were ERβ agonists,
while all extracts antagonized ERα. In the transrepression
model, however, the behavior of the Cyclopia extracts became
more complex. P104, which displayed opposite effects via the
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Figure 7.  Evaluation of the in vivo effect of E2, genistein and SM6Met on immature rat uterine growth.  Immature female
wistar rats were treated with 100µg/kg body weight E2, in the presence and absence of 2000mg/kg body weight SM6Met or 10mg/kg
body weight ICI 182,780, 100mg/kg body weight genistein, 2000mg/kg body weight SM6Met, and 10mg/kg body weight ICI 182,780
for three consecutive days. Animals were sacrificed on day four, (A) uteri were photographed, and (B) wet uterine/final body weight
was determined. One-way ANOVA with Dunnett’s post-test comparing all columns to either solvent control (*, P<0.05; **, P<0.01;
***, P<0.001) or E2 (#, P<0.05; ##, P<0.01; ###, P<0.001). The dotted lines through the bars represent the values for solvent control
or E2. Average ± SEM is of at least five animals/group.
doi: 10.1371/journal.pone.0079223.g007
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subtypes in the transactivation model, acted as an agonist for
both subtypes in the transrepression model. The extracts of C.
subternata, however, did not elicit such uniform effects in the
transrepression model. SM6Met, a methanol extract, acting as
an ERα antagonist and ERβ agonist regarding transactivation,
displayed antagonism towards ERα, in the absence of E2, and
towards ERβ, in the presence of E2. Similar antagonism
towards ERα in the absence of E2 has also been seen for the
plant extract MF101 regarding IL6 mRNA expression [24]. The
water extract, cup-of-tea, also changed its behavior, acting as
an ERβ antagonist for transrepression as opposed to an ERα
antagonist for transactivation. These behavioral changes were
not exclusive to the Cyclopia extracts as the polyphenols also
displayed these characteristics. Luteolin, for example,
displayed ER agonism through both subtypes in the
transactivation model but was an ERα agonist and an ERβ
antagonist in the transrepression model. The occurrence of
mixed agonism and antagonism towards ER subtypes has also
been observed for the xenoestrogen, Bisphenol A (BPA) [107].
As the current experiments were performed in the same cell
line we have to look towards differences between the
mechanisms of transactivation and transrepression for
clarification of these results. Classically, transactivation is a
product of ER dimer binding directly to the DNA sequence,
however, tethering to DNA bound transcription factors (TFs) in
the promoter region of affected genes has also been described
[108-111]. Binding of the ER to DNA, whether it is direct or
indirect, initiates the recruitment of co-activators, which then
modulates transcription [112]. Regarding transrepression,
specifically the repression of NFκB driven genes, various
mechanisms of ER mediated transrepression have been
described [109]. The ER can bind to NFκB and thereby prevent
Figure 8.  Evaluation of the effect of E2 and SM6Met on the timing of vaginal opening.  Immature female wistar rats were
treated for 30 consecutive days with 100μg/kg body weight E2 and 2000mg/kg body weight SM6Met and the day of vaginal opening
was determined. One-way ANOVA with Dunnett’s post-test comparing all columns to solvent control (*, P<0.05; **, P<0.01; ***,
P<0.001). The dotted line through the bars represents the values for solvent control. Average ± SEM is of at least eight animals/
group.
doi: 10.1371/journal.pone.0079223.g008
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DNA binding of the transcription factor [113,114], ligand bound
ER present at promoter regions can recruit co-repressors
[115,116], ligand bound ERα and activated NFκB can compete
for co-activator recruitment [117,118], or ERα, through a non-
genomic pathway, inhibits translocation of activated NFκB to
the nucleus [119]. We can use this knowledge of the
mechanism of action and combine it with what we know about
SERMs and ER subtypes specific ligands to postulate a
mechanism of action of Cyclopia agonism and antagonism. For
the SERMs, three mechanisms of antagonism have been
proposed [18]. SERMs can bind to the ER with a higher affinity
than E2 and block the binding of E2, they can block the binding
of co-activators, or SERMs can induce the recruitment of co-
repressors [18,120,121].. Not much is known regarding the
mechanism of SERM agonism [18], although it has been
suggested that they can block the binding of co-repressors
[121]. In addition, MF101 and liquiritigenin, both ERβ selective
agonists, although being able to bind to ERα, cannot recruit co-
activators to ERα, and MF101 cannot promote the interaction
of ERα with regulatory elements [15,24]. Furthermore, it has
been suggested that SERMs may activate cell surface
signaling pathways that results in ligand-independent activation
of ERs [29,122,123].
Therefore, with regards to transactivation, we may postulate
that the extracts of Cyclopia cannot transactivate via ERα as
they are unable to recruit the necessary co-activators, while for
ERβ, P104 and SM6Met are able to do so. It is also possible
that the extracts of Cyclopia cannot induce ERα interaction with
regulatory elements. The observed ERα antagonism of E2-
induced transactivation may be due to the extracts binding to
ERα and either inhibiting E2 binding, inhibiting the recruitment
of co-activators or stimulating the recruitment of co-repressors.
In our transrepression model P104 behaves like E2 and could
be exerting its function by any of the NFκB repression models
discussed earlier. However, SM6Met displays ERα antagonism
in the absence of E2 and this antagonism is lost in the presence
of E2. Therefore, it is possible that SM6Met is unable to recruit
co-repressors in the absence of E2 and is unable to inhibit the
E2-induced recruitment of co-repressors. Furthermore,
antagonism of ERβ in the transrepression model by SM6Met
and cup-of-tea may be due to the recruitment of co-activators
to ERβ.
Next we evaluated agonism and antagonism of Cyclopia
extracts in a more complex environment where the ER
subtypes are co-expressed. We used the MCF-7BUS cells, a
breast carcinoma cell line, not only because it co-expresses the
subtypes (Figure 2A), but also to evaluate the activity of the
extracts in breast tissue cells. With regards to transactivation,
all extracts of Cyclopia were agonists and are likely exerting
this agonism through ERβ as they were ERβ agonists and ERα
antagonists in COS-1 cells. Also, previously we discussed the
possibility that the extracts may be unable to recruit co-
activators to ERα or induce ERα-regulatory element
interactions, which supports the idea that the Cyclopia extracts
are mediating their transactivative effects in MCF-7BUS cells
via ERβ. Interestingly, the polyphenols, genistein and luteolin,
having displayed ER agonism in COS-1 cells, in an
environment where both ER subtypes are present displayed
only weak agonism, which may be attributed to the fact that
lower concentrations were used in MCF-7BUS cells. However,
when both subtypes are present these polyphenols display
antagonism, which was not apparent when the subtypes were
expressed separately. When both ER subtypes are expressed
in the transrepression model, all the polyphenols as well as the
Cyclopia extracts acted as agonists, while the water extract of
C. subternata also displayed ER antagonism. The ER agonism
of P104 in the transrepression model is thus not a cell type
selective effect as it is seen in both the COS-1 (kidney) and
MCF-7BUS (breast) cells. The ER antagonism of cup-of-tea in
MCF-7BUS cells is likely mediated via ERβ as ERβ antagonism
was observed in COS-1 cells transfected with ERβ, but not in
cells transfected with ERα. However, the SM6Met extract,
which displayed antagonism for ERα and ERβ in COS-1 cells,
changes its behavior in the MCF-7BUS cells and acts as an ER
agonist in the transrepression model. Furthermore, a similar
switch in behavior is observed with the polyphenols as the
subtype specific antagonism is abrogated in the presence of
both ER subtypes. These observed behavioral changes of the
Cyclopia extracts as well as the polyphenols in different tissues
have also been observed for the SERM, tamoxifen [18]. Ball et
al. [18] found that tamoxifen differentially regulated ER
regulated genes in different cell lines and ascribed this
phenomenon to the presence, or lack of, co-regulators in
different tissues. Therefore, the differential effect of Cyclopia
extracts as well as the polyphenols in cells from different
tissues might be due to changes in the co-regulator
environment.
As MCF-7BUS cells express both ER subtypes, we also
have to consider the possibility of ERα/β heterodimer formation
and the biological relevance thereof as opposed to homodimer
formation in COS-1 cells expressing the ER subtypes in
isolation. Using two phytoestrogens that are ERα/β
heterodimer selective, cosmosiin and angolensin, it was shown
that heterodimer formation, in the presence of these ligands,
leads to higher activation of an ERE-promoter reporter
construct than homodimers and furthermore that heterodimer
formation has a growth inhibitory effect in breast and prostate
epithelial cells [124]. Previous studies by Powell et al. [46]
showed that the ERβ selective agonist, liquiritigenin, which can
bind to both ER subtypes, induces an ERα conformation that
prefers heterodimerization with ERβ, as opposed to forming
ERα homodimers. Therefore, we cannot exclude heterodimer
formation as an explanation for the strong agonist effect of the
Cylopia extracts in the transactivation model in MCF-7BUS
cells.
Having evaluated the agonist and antagonist activity of
Cyclopia extracts in a system where the ER subtypes were
expressed separately and together, in a transactivation and a
transrepression model, we increased the level of complexity by
evaluating the effect of the extracts on MCF-7BUS cell
proliferation, a system where the final cell phenotype is a
product of not only the two ER subtypes but also of an
integrated transactivation and transrepression system
[39,98-100]. Although the Cyclopia extracts, like E2, induced
cell proliferation it was with either a significantly lower potency
(P104 and SM6Met) or lower efficacy (P104 and cup-of-tea)
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than E2. Furthermore, in the presence of E2, all of the Cyclopia
extracts displayed antagonistic properties. Similarly, the
polyphenols also induced cell proliferation with either lower
efficacies or potencies than E2 and some (genistein and
enterodiol) also displayed antagonism. Previously, the agonist
activity seen in the transactivation model in MCF-7BUS cells
was ascribed to ERβ activation and this is probably translating
into weak induction of MCF-7BUS cell proliferation.
Furthermore, liquiritigenin, an ERβ selective agonist, although
not able to induce significant MCF-7 cell growth in a mouse
xenograft model [19,24], was able to induce proliferation of the
ERα and ERβ positive [125] osteoblast-like murine MC3T3-E1
cells [126]. The antagonism of E2-induced cell proliferation by
extracts of Cyclopia could be attributed to ERα antagonism
(observed in the transactivation model in COS-1 cells), ER
mediated repression of proliferation inducing genes (ER
transrepression observed in MCF-7BUS transrepression
model), ERβ-mediated transcription (observed in the
transactivation model in COS-1 cells) of anti-proliferative and
anti-apoptotic genes [39,127], or they might favor the formation
of ERα/β heterodimers, which has been suggested to have
growth inhibitory effects in breast epithelial cells [124].
Furthermore, we also evaluated the estrogenic and
antiestrogenic properties of the Cyclopia extracts in an in vivo
model, an immature rat uterotrophic assay. For the first time we
show in vivo biological activity of the phytoestrogenic extracts
of Cyclopia. SM6Met and cup-of-tea, unlike E2 and genistein,
did not increase uterine weight and SM6Met, like the ER
antagonist ICI 182,780, antagonized E2-induced uterine growth.
The ERα subtype is the major subtype expressed in the uterus
with very low levels of ERβ expressed [56,101]. Powell et al.
[46] show that although ERβ homodimers and ERα/ERβ
heterodimers are favored, genistein is capable of inducing ERα
homodimers and activating ERα-induced transcription.
Therefore, we can assume that the increase in uterine growth
induced by genistein in the uterotrophic assay is a product of
increased ERα homodimerization and hence, increased ERα
mediated transcription. The ERβ selective agonists,
liquiritigenin and ERB-041, in contrast, do not induce uterine
growth [19,128]. Thus, the findings regarding ERβ selective
agonists combined with the low levels of ERβ in the uterus
excludes ERβ as the subtype eliciting the effect of Cyclopia
extracts in the uterus. It is thus likely that the effect of Cyclopia
extracts is due to ERα antagonism, as seen in the
transactivation model in COS-1 cells, or that upon binding to
the ER, the Cyclopia extracts induce a change in conformation
that inhibits co-activator recruitment or activates co-repressor
recruitment. The inability of the Cyclopia extracts to induce
uterine growth, in contrast to MCF-7BUS cell proliferation,
might also be attributed to either the differences in the
concentration of co-regulators or the differences in co-regulator
recruitment in the breast and uterus [129,130].
Having established ER agonist and/or antagonist activity of
Cyclopia extracts, we look towards HPLC data, from the
current and previous studies, to identify the polyphenol(s)
responsible for the observed effects. The xanthones,
mangiferin and isomangiferin, were identified in all Cyclopia
extracts, but as mangiferin has no estrogenic potential, while
isomangiferin has not previously been tested for estrogenicity
[71], it is unlikely that the observed ER agonist/antagonist
effects of Cyclopia can be ascribed to these polyphenols.
However, mangiferin has been shown to inhibit the proliferation
of breast cancer cells via ER independent mechanisms [131]
and therefore, as mangiferin is present in all extracts at
relatively high amounts it cannot be excluded as the polyphenol
antagonizing E2-induced MCF-7BUS cell proliferation. Of the
remaining polyphenols identified in the extracts the only
aglycone present is the flavone, luteolin. In vitro, luteolin binds
to both of the ER subtypes, is an ERα and ERβ agonist,
induces MCF-7BUS cell proliferation, and antagonizes E2-
induced MCF-7BUS cell proliferation [62,63,71,132-134].
Therefore, with regards to the Cyclopia extracts, the ERβ
agonism observed in the transactivation model, the induction of
MCF-7BUS cell proliferation, and the antagonism of E2-induced
cell proliferation may be ascribed to the presence luteolin in the
extracts, however, the observed ERα antagonism in the
transactivation model cannot. Although luteolin is present in all
extracts, the concentration is low. However, the 7-O-rutinoside
of luteolin, scolymoside, is present in substantial amounts in all
of the C. subternata extracts (presence was not evaluated in
P104). This rutinoside of luteolin has not previously been
tested for estrogenicity [71], however, as glycosides may be
hydrolyzed by intestinal β-glucosidases [135,136], the
bioavailability of the aglycone, luteolin, and hence
phytoestogenicity of the extracts may increase upon hydrolysis
of scolymoside. Furthermore, luteolin has been shown to have
anti-tumor characteristics and can sensitize breast cancer cells
to anti-tumor drugs such as tamoxifen [137] and therefore, the
presence of luteolin, as well as scolymoside, in Cylopia
extracts can be seen as positive regarding chemoprevention as
well as breast cancer treatment. Generally, the glycosides of
polyphenols either display reduced estrogenic activity
compared to the aglycones or have not been evaluated for
estrogenicity [71]. Thus, if the hydrolysis of glycosides present
in the Cyclopia extracts is considered, it allows us to evaluate
the phytoestrogenicity of the aglycones alongside their
glycosides: apigenin (aglycone of vicenin-2), eriodictyol
(eriocitrin), hesperitin (hesperidin), phloretin (phloretin-3,5-di-C-
glucoside), hydroxyphloretin (3-hydroxyphloretin-3’,5’-di-C-
hexoside), and iriflophenone (iriflophenone-2-C-β-glucoside
and iriflophenone-di-O,C-hexoside). However, as β-
glucosidases are produced by intestinal flora [138,139],
consideration of glycoside metabolism will not help to identify
the polyphenols responsible for in vitro results but may only be
relevant for interpretation of in vivo results. For example, as
luteolin and apigenin have been shown to significantly increase
uterine weight, either in the presence or absence of estrogens
[140,141], the effect elicited by Cyclopia extracts in vivo cannot
be ascribed to luteolin, scolymoside, or vicenin-2. The effect of
the other identified polyphenols has not been evaluated in vivo
and therefore we cannot definitively attribute the in vivo effect
of the Cyclopia extracts to any of these polyphenols. Of the
glycosides, ericotrin and hesperidin have been tested for
phytoestrogenicity in vitro [71]. However, hesperidin does not
bind to the ER [62] or activate an ERE-containing promoter
reporter construct [133]. Eriocitrin, however, has been shown to
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bind to only ERβ [62], but no work has been done to elucidate
the estrogenic effect elicited by this polyphenol. For the first
time we identified the dihydrochalcone, aspalathin, in Cyclopia.
Aspalathin has not been tested for estrogenicity but has been
shown to inhibit the proliferation of liver cells [142], however,
due to the presence of unique drug metabolizing enzymes in
the liver, the possibility of aspalathin metabolites eliciting this
effect cannot be excluded nor can the results be extrapolated
to breast cancer cells. The phytoestrogenicity of the remaining
glycosides and aglycones, as well as protocatechuic acid, has
not been tested [71]. In summary, none of the compounds
identified in the Cyclopia extracts can account for the observed
ERα antagonism, some (luteolin and eriocitrin) may explain the
observed ERβ agonism and others (mangiferin and aspalathin)
should not be excluded as possible effectors of ER-
independent effects on proliferation. Therefore, thus far, we
cannot with certainty ascribe the effects observed with Cyclopia
extracts in this study to any of the individual constituents of our
extracts. Although, further research regarding the polyphenol
content, bioavailability, and estrogenic activity of our extracts is
required to identify the compound causing the observed
effects, we cannot exclude the possibility that a mixture of
polyphenols is required to elicit the effects observed with
Cyclopia extracts.
Physiologically, our results may be assessed both in terms of
treatment of menopausal symptoms (hot flashes, osteoporosis,
and increased inflammation [2-4,52,90-92]) and prevention of
estrogen replacement associated side effects (breast cancer
and uterine proliferation [5,6,52]). With regards to menopausal
symptoms, the ERβ agonist MF101 [24], has been shown in
clinical trials to reduce hot flashes and thus, the ERβ agonism
of the Cyclopia extracts may be considered as a positive
attribute. Furthermore, with regards to the postmenopausal
surge in inflammatory disorders the fact that the Cyclopia
extracts displayed agonism in the transrepression model in
MCF-7BUS cells may also be considered as a positive attribute
for the treatment of postmenopausal inflammatory disorders.
With respect to the known roles of ER subtypes in breast
cancer [15,22,37-43], the fact that extracts of Cyclopia
antagonize ERα, while being ERβ agonists, may be beneficial.
In addition, the extracts were able to antagonize the
proliferation of breast cancer cells in the presence of E2 at
lower concentrations than that required for breast cancer cell
proliferation. Furthermore, not only do the Cyclopia extracts
show potential as protectors against breast cancer
development and inflammatory disorders, they also do this
without promoting uterine growth, a negative SERM associated
side effect [35,143].
Although Cyclopia extracts show potential to be developed
as SERSMs, further work, which is ongoing, is needed to clarify
their mechanism of action. This includes, but is not limited to,
directly comparing the Cyclopia extracts with the known
SERMs tamoxifen and raloxifene, investigating the effect of
Cyclopia extracts on ER subtype levels, ER homo- or
heterodimerization, induction or inhibition of co-regulator
recruitment, and the modulation of cancer development and
progression in a rat breast cancer model. In addition, further
work is needed to identify the polyphenol(s) responsible for
eliciting the observed effects and the possibility that distinct
polyphenols present in Cyclopia, rather than an individual
polyphenol, may be causing the observed ERα agonism and
ERβ antagonism cannot be excluded.
Supporting Information
Figure S1.  Determination of ERE-containing promoter
reporter construct concentration. (A & B) COS-1 cells,
transfected with equal amounts of (A) ERα and (B) ERβ, and
(C) MCF-7BUS cells were transfected with increasing amounts
of the ERE-containing promoter reporter construct
(ERE.vit2.luc) and treated with either solvent or E2 to determine
at which concentration of the ERE-containing promoter reporter
construct the highest induction of E2 is observed. The dotted
line through the bars represents the values for solvent control.
Fold induction is indicated in boxes above the E2 columns.
Average ± SEM is of one experiment done with three to four
repeats.
(TIF)
Figure S2.  Determination of NFκB-containing promoter
reporter construct concentration. (A & B) COS-1 cells,
transfected with equal amounts of (A) ERα and (B) ERβ, and
(C) MCF-7BUS cells were transfected with increasing amounts
of the NFκB-containing promoter reporter construct
(p(IL6kB)350hu.IL6Pluc+) and treated with either solvent, PMA
or PMA + E2 to determine at which concentration of the NFκB-
containing promoter reporter construct the highest repression
by E2 of PMA induction is observed. The dotted lines through
the bars represent the values for either solvent control or
10ng/ml PMA. Percentage repression, where applicable, is
indicated in boxes above the PMA + E2 columns. Average ±
SEM is of one experiment done with three repeats.
(TIF)
Figure S3.  The effect of the SM6Met and cup-of-tea
extracts on immature rat uterine growth. Immature female
wistar rats were treated with 2000, 200, and 20mg/kg body
weight SM6Met and cup-of-tea for three consecutive days.
Animals were sacrificed on day four, (A) uteri were
photographed and (B) wet and (C) blotted uterine/final body
weight was determined. One-way ANOVA with Dunnett’s post-
test comparing all columns to solvent control (*, P<0.05; **,
P<0.01; ***, P<0.001). The dotted line through the bars
represents the values for solvent control. Average ± SEM is of
at least eight animals/group.
(TIF)
Figure S4.  The effect of E2, genistein, extracts of Cyclopia,
and ICI on body and liver weight. Immature female wistar
rats were treated for three consecutive days with 100µg/kg
body weight (BW) E2, in the presence and absence of
2000mg/kg BW SM6Met or 10mg/kg BW ICI 182,780,
100mg/kg BW genistein, 2000, 200, or 20mg/kg BW SM6Met,
2000, 200, or 20mg/kg BW cup-of-tea, and 10mg/kg BW ICI
182,780 for three consecutive days. Animal were sacrificed on
day four and changes in (A) body and (B) liver weights were
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determined. One-way ANOVA with Dunnett’s post-test
comparing all columns to solvent control (*, P<0.05; **, P<0.01;
***, P<0.001). The dotted line through the bars represents the
values for solvent control (A and B) and 100µg/kg BW E2 (A).
Average ± SEM is of at least five animals/group.
(TIF)
Figure S5.  The effect of different concentration of the
SM6Met and cup-of-tea extracts on the onset of vaginal
opening. Immature female wistar rats were treated for 30
consecutive days with the SM6Met and cup-of-tea extracts and
the day of vaginal opening was determined. One-way ANOVA
with Dunnett’s post-test comparing all columns to solvent
control (*, P<0.05; **, P<0.01; ***, P<0.001). The dotted line
through the bars represents the values for solvent control.
Average ± SEM is of at least eight animals/group.
(TIF)
Table S1.  Summary of ER agonism and antagonism of
Cyclopia extracts.
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